2019
A phase II study of pembrolizumab in combination with palliative radiotherapy (RT) for hormone receptor-positive (HR+) metastatic breast cancer (MBC).
Barroso-Sousa R, Krop I, Trippa L, Tan-Wasielewski Z, Li T, Osmani W, Andrews C, Dillon D, Richardson E, Winer E, Mittendorf E, Schoenfeld J, Tolaney S. A phase II study of pembrolizumab in combination with palliative radiotherapy (RT) for hormone receptor-positive (HR+) metastatic breast cancer (MBC). Journal Of Clinical Oncology 2019, 37: 1047-1047. DOI: 10.1200/jco.2019.37.15_suppl.1047.Peer-Reviewed Original ResearchMetastatic breast cancerNeutrophil/lymphocyte ratioObjective response rateProgression-free survivalTumor-infiltrating lymphocytesPalliative radiotherapyAdverse eventsHormone receptor-positive metastatic breast cancerPhase II single-arm studyMedian progression-free survivalCause adverse eventsDistant tumor responsesECOG PS 1Prior cytotoxic therapyImmune checkpoint inhibitorsPD-L1 expressionPD-L1 statusPhase II studySingle-arm studyTotal RT doseUnexpected adverse eventsECOG PSEligible ptsRECIST v1.1Measurable lesions
2017
False Positive Positron Emission Tomography / Computed Tomography Scans in Treated Head and Neck Cancers
Cheung MK, Ong SY, Goyal U, Wertheim BC, Hsu CC, Yi SK. False Positive Positron Emission Tomography / Computed Tomography Scans in Treated Head and Neck Cancers. Cureus 2017, 9: e1146. PMID: 28497009, PMCID: PMC5425288, DOI: 10.7759/cureus.1146.Peer-Reviewed Original ResearchPost-treatment PET/CT scansPET/CTPET/CT scansPET/CT studiesSquamous cell carcinomaFalse positivityNegative predictive valuePost-treatment settingRadiation therapyPredictive valueNeck cancerCT scanExact testPositive PET/CT studiesCT studiesPost-treatment PET/CTPositron emission tomography/High negative predictive valueCareful multidisciplinary discussionPrimary disease stageRetrospective chart reviewTotal RT doseEmission tomography/Primary tumor siteSerum glucose levels
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply